Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 9, 2012, Pages 1551-1560

  Knez, L ^a   Kosnik M ^a   Ovcaricek T ^b   Sadikov, A ^c   Sodja, E ^a   Kern, I ^a   Cufer, T ^a  

^a University Hospital Golnik   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

ABCB1 protein; Chemotherapy; Genetic polymorphisms; Multiple drug resistance; Small cell lung cancer

Indexed keywords

ABC TRANSPORTER A1; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; CHEMORADIOTHERAPY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; ETOPOSIDE; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SMALL CELL LUNG CARCINOMA; VINCRISTINE;

EID: 84866742838     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1231-1     Document Type: Article

References (34)

1. Arvelo F, Poupon MF, Goguel AF, Lizard G, Burgeois Y, Arriagada R et al (1993) Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy. J Canc Res Clin Oncol 120:17-23
2. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D et al (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophos-phamide. Br J Cancer 102:1003-1009
3. Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F et al (2007) MDR1 polymorphism in Xuences the outcome of multiple myeloma patients. Br J Haematol 137:454-456
4. Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH et al (2010) Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 89:1133-1140
5. Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS et al (2009) Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20:272-277
6. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373-383
7. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008) GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC cancer base no. 10. International Agency for Research on Cancer, Lyon
8. Fung KL, Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794:860-871
9. Green H, Söderkvist P, Rosenberg P, Horvath G, Peterson C (2006) mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12:854-859
10. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY et al (2007) Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan- pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110:138-147
11. Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, Tsai PC et al (2010) Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with Wrst-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 21:18-25
12. Hüebener C, Petermann I, Browning BL, Shelling AN, Ferguson LR (2007) Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677T/A as an example. Cancer Epidemiol Biomarkers Prev 16:1185-1192
13. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S et al (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955-4962
14. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M et al (2004) Single nucleotide polymorphisms and outcome n docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194-1203
15. Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM et al (2008) ABCB1 (MDR1) polymorphisms and progression-free sur-vival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 14:5594-5601
16. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199
17. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al (2007) A "silent" polymorphism in the MDR1 gene changes substrate speciWcity. Science 315:525-528
18. Knez L, Sodja E, Kern I, Košnik M, Cufer T (2011) Predictive value of multidrug resistance proteins, topoisomerase II and ERCC1 in small cell lung cancer: a systematic review. Lung Cancer 72:271-279
19. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ et al (2003) Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-494
20. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530-2535
21. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxanes chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 25:4528-4535
22. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
23. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ (2008) MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75:380-385
24. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ (2009) MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 78:49-55
25. Shitara K, Matsuo K, Ito S, Sawaki A, Kawai H, Yokota T et al (2010) EVects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac J Cancer Prev 11:447-452
26. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM et al (2008) ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen independent prostate cancer treated with docteaxel. Clin Cancer Res 14:4543-4549
27. Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH et al (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36:137-141
28. Sørensen M, Pijls-Johannesma M, Felip E, ESMO Guidelines Working Group (2010) Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v120-v125
29. Stewart DJ (2010) Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75:173-234
30. Tang K, Wong LP, Lee EJ, Chong SS, Lee CG (2004) Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet 13:783-797
31. Tregouet DA, Tiret L (2004) Cox proportional hazards survival regression in haplotype-based association analysis using the stochastic-EM algorithm. Eur J Hum Genet 12:971-974
32. van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, van der Holt B, Vossebeld PJ, Pieters R et al (2001) MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 97:3605-3611
33. Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM et al (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71:191-198
34. Zhou J (2010) Multi-drug resistance in cancer, 1st edn. Humana Press, New York